brentuximab vedotin (Adcetris)

following a full submission under the orphan equivalent medicine process:

brentuximab vedotin (Adcetris®) is accepted for use within NHSScotland.

Indication under review: for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).

In an open-label, phase III study, six cycles of brentuximab vedotin (in combination with AVD) compared with six cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine), significantly improved modified progression-free survival in adults with previously untreated CD30+ Stage III or IV HL.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.